Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients.

Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients.
复制标题

磷酸化 eIF2 α 可预测三阴性乳腺癌患者的无病生存期

DOI:
10.1038/srep44674
复制
发表时间:
2017-03-15
期刊:
影响因子:
4.6
通讯作者:
Wu J
Wu J
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Guo L;Chi Y;Xue J;Ma L;Shao Z;Wu J

文献摘要

被引文献

相似文献

磷酸化的真核生物翻译起始因子2α(p-eIF 2 α)作为内质网应激的标志物,已被报道与多种癌症的患者预后相关。然而,对p-eIF 2 α在乳腺癌中的预后价值知之甚少,特别是在不同的乳腺癌亚型中。使用包含233个肿瘤和来自诊断为乳腺癌的女性患者的配对瘤周组织的组织微阵列进行p-eIF 2 α的免疫组织化学筛查。对染色结果进行半定量评分,探讨p-eIF 2 α在乳腺癌中的表达水平及其潜在的预后价值。在这项回顾性队列研究中,我们发现p-eIF 2 α水平在乳腺癌中显著上调(P < 0.001)。p-eIF 2 α水平与淋巴结转移呈负相关(P = 0.039)。Kaplan-Meier估计和考克斯回归分析显示,p-eIF 2 α水平与三阴性乳腺癌患者的无病生存率相关(P = 0.026),并可作为三阴性乳腺癌患者的独立预后因素(P = 0.046)。我们的研究表明,p-eIF 2 α在乳腺癌中上调,并代表了三阴性亚型患者预后的新预测因子。
Phosphorylated eukaryotic translation initiation factor 2α (p-eIF2α), which functions as a marker of endoplasmic reticulum stress, has been reported to be associated with patient prognosis in various cancers. However, little is known about the prognostic value of p-eIF2α in breast cancer, particularly in different breast cancer subtypes. An immunohistochemistry screen for p-eIF2α was performed using a tissue microarray containing 233 tumors and paired peritumoral tissues from female patients diagnosed with breast cancer. The staining results were scored semiquantitatively, and the p-eIF2α expression level in breast cancer and its potential prognostic value were investigated. In this retrospective cohort study, we found that p-eIF2α levels were significantly upregulated in breast cancer (P < 0.001). p-eIF2α level was negatively correlated with lymph node status (P = 0.039). Survival analysis by Kaplan–Meier estimation and Cox regression showed that p-eIF2α level was correlated with better disease free survival (P = 0.026) and served as an independent prognostic factor (P = 0.046) in patients with triple-negative breast cancer. Our study revealed that p-eIF2α was upregulated in breast cancer and represented a novel predictor of prognosis in patients with triple-negative subtype.